Background: Arrhythmogenic cardiomyopathy (AC) is an autosomal dominant inherited disease with incomplete penetrance and variable expression, and an important cause of sudden cardiac death in young adults. In the absence of genetic diagnosis, long-term follow-up of all first degree relatives is mandatory. Although the reported yield of the genetic test in AC probands is 50-60%, there is scarce data on the economic impact of the genetic cascade screening strategy. Objectives: To study the cost-effectiveness of the genetic cascade strategy in AC families. Methods: 151 patients from 41 families were consecutively enrolled in a Spanish referral Inherited Heart Disease centre. The cost of the genetic testing in each family was calculated adding the price of the proband study (NGS panel, 1380(NGS panel, in 2015 and cascade genetic screening ( 200 each patient). The estimated price of the clinical work-up and follow-up of relatives without causal mutations who were discharge after genetic testing computed as cost-savings (diagnostic workup costs 819; follow-up visit costs 236/each). Incremental cost was the difference between the cost of genetic testing and the cost-savings generated by the genetic results. We also calculated the number of patients in each family who obtained benefit from the information provided by the genetic test. Results: We found 19 pathogenic mutations in 20 probands (detection rate = 49%), and 13 variants of unknown significance among the five main desmosomic genes (PKP2, DSP, DSG2, DSC2 and JUP). Among relatives, 12 had AC, 10 borderline diagnosis and 25 were carriers of mutation. 22 non-carriers could be discharge. The total incremental cost of the genetic cascade strategy was 12,514 (41 probands and 68 relatives genotyped) and 69 individuals benefit specifically from genetic results information. The incremental cost per causal mutation is 626 and the cost-per-patient benefit is 181 (Figure 1, red dot) . Simulation studies showed that this strategy would be cost-saving if the price of the proband's genetic test was below 1074. The number of mayor diagnostic criteria in the proband (excluding genetics), and the number of children at risk (<14 years old) were independent predictors of the cost-effectiveness ratio in each family (p<0.011 for both). Background and purpose: Arrhythmogenic cardiomyopathy (AC) is a genetic heart muscle disorder characterized by fibro-fatty replacement of cardiomyocytes, cardiac remodeling leading to life threatening ventricular arrhythmias, heart failure and sudden cardiac death. Genes encoding cardiac junctional proteins are known to cause about 50% of cases, while remaining causes are unknown. The sequence of cellular and molecular events leading to arrhythmias and heart failure is poorly understood.
. Cost-effectiveness chart Conclusion: Genetic cascade strategy for familial screening in AC is costeffective with a willingness to pay of 181 per patient benefit. The relationship between the incremental cost and benefits in each family depends on the phenotype of the proband and the number of pediatric relatives. Background and purpose: Arrhythmogenic cardiomyopathy (AC) is a genetic heart muscle disorder characterized by fibro-fatty replacement of cardiomyocytes, cardiac remodeling leading to life threatening ventricular arrhythmias, heart failure and sudden cardiac death. Genes encoding cardiac junctional proteins are known to cause about 50% of cases, while remaining causes are unknown. The sequence of cellular and molecular events leading to arrhythmias and heart failure is poorly understood.
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Methods and results:
We clinically evaluated a family with AC with an early onset in children. The index case, a 14-year old girl died suddenly and autopsy revealed AC. Three other siblings at the ages of 12, 22 and 24 years were also affected by the disease and had defibrillators implanted. Whole exome analyses identified a novel variant in a new disease gene involved in cell-extracellular matrix connection: Integrin linked Kinase (ILK). We also found a second variant in another child with AC which appeared to be de novo. Localization experiments of mutant and wild-type ILK in transfected H9c2 and C2C12 cells demonstrated an aberrant cytoplasmic localization in cells transfected with mutant ILK. Next, we developed several transgenic zebrafish lines expressing human wildtype and three mutants of ILK under the control of the cardiac-specific myl7 promotor, and found that two of the mutant alleles are lethal before about 2-3 weeks of age (i.e. larval stages). We developed two hypotheses: (1) mutant fish die due to progressing heart failure or (2) due to electrical problems leading to arrhythmias and sudden death. Fractional shortening was measured as an indicator of heart failure, and was decreased at 3dpf in both mutants. Next, we established a technique to patch the atrium and ventricle directly at 3dpf to determine action potentials. However, we found no significant difference between wildtype and mutant embryos. We continue further experiments to determine the cause of death in mutant fish. Conclusion: We identified two novel missense variants in the ILK gene in two unrelated families. ILK is an important linker protein involved in the cell -extra cellular matrix adhesion. Our in vitro and in vivo experiments demonstrated the pathogenic potential of these variants justifying the classification as "likely pathogenic". In conclusion, we present genetic and functional evidence that ILK might have relevance for diagnosis and genetic counseling of the disease in the future. Background: Anterior T wave inversion (ATWI) is a common ECG feature of arrhythmogenic right ventricular cardiomyopathy (ARVC). ATWI is not always pathological and may be a marker of physiological adaptation to exercise in elite athletes and is present in young non-athletes or in individuals engaging recreational sports. The aim of the study was to investigate the prevalence of ATWI in a large cohort of ARVC; we then sought to compare ATWI in ARVC and healthy individuals.
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Methods:
The study population consisted of 1) patients with definite diagnosis of ARVC according to the Revised Task Force criteria (n=162, mean age 41±16, males 67%) and 2) young (mean age 22±6, males 44%, Caucasian 90%) healthy individuals with ATWI, including elite athletes (n=29) and young non-athletes/recreational athletes (n=100 
